Clinical Activity and Cardiac Tolerability of Non-Pegylated Liposomal Doxorubicin in Breast Cancer: A Synthetic Review
暂无分享,去创建一个
S. Barni | D. Amadori | S. Iacobelli | P. Marchetti | V. Lorusso | A. Di Leo | R. Mattioli | G. Minotti | C. Tondini | P. Pronzato | G. Rosti | S. Cinieri | A. Gennari | M. Ionta | M. Lotrionte | M. Airoldi | A. Veronesi | S. De Placido
[1] E. Winer,et al. Cardiovascular safety of adjuvant bevacizumab for breast cancer. , 2010 .
[2] H. Caron,et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.
[3] E. Winer,et al. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. , 2009, Clinical breast cancer.
[4] C. Hudis. Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.
[5] B. Nathwani,et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Ricci,et al. Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy , 2004, British Journal of Cancer.
[7] A. Rodger. Management of breast cancer. , 1992, BMJ.
[8] G. Hortobagyi,et al. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin‐containing regimens , 1981, Cancer.